Cambridge Epigenetics

The IP stems from the work of Anjana Rao, who identified 5-hydroxymethylcytosine (5hmC) as a cancer diagnostic biomarker.

While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.

The company was founded as a spinout of the University of Cambridge to commercialize an epigenetic sequencing technique called oxidative bisulfite sequencing.

Lab7 Systems has released a beta version of its next-generation sequencing data workflow management software platform, available for download to early-access users from the company's website. The company is planning updates to the software every four to six weeks.

This article was originally published May 17.
Startup firm Cambridge Epigenetix plans to commercialize an epigenetic sequencing technique, with the launch of its first product — called TrueMethyl — expected in August.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.